Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Highlighting Integration of Clinical Innovation, Multi-Omics, and AI for Solid Tumor Therapies
Candel Therapeutics delivered three major presentations at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, November 5–9, 2025, in National Harbor, Maryland34.
Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and CEO, presented positive phase 3 clinical trial data for CAN-2409 in newly diagnosed localized prostate cancer, which achieved its primary and secondary endpoints; the company intends to submit a Biologics License Application (BLA) for CAN-2409 in prostate cancer in Q4 202634.
A multi-omics analysis of CAN-2409 in non-small cell lung cancer (NSCLC), presented by Daniel Sterman, M.D. (NYU Langone Health), identified immune signatures distinguishing response patterns in non-squamous subtypes, offering insights into mechanisms of tumor response34.
Anne Diers, Ph.D., showcased preclinical validation of the enLIGHTEN™ Discovery Platform, where AI-designed viral immunotherapies achieved 60% tumor growth suppression and robust immune activation in breast cancer models; this work confirms the platform’s potential for accelerating precision immunotherapy design34.
Candel emphasized its leadership in integrating clinical innovation, multi-omics insights, and artificial intelligence (AI) to advance next-generation immunotherapies targeting multiple solid tumors34.
The company’s iterative research approach leverages advanced tools to generate deep biological insights that inform each stage of drug development, aiming to improve clinical outcomes for patients with difficult-to-treat cancers34.
Sources:
3. https://www.globenewswire.com/news-release/2025/11/04/3180386/0/en/Candel-Therapeutics-Showcases-Immunotherapy-Leadership-at-SITC-2025-Demonstrating-Integration-of-Clinical-Innovation-Multi-Omics-and-Artificial-Intelligence-to-Advance-Next-Generat.html
4. https://www.biospace.com/press-releases/candel-therapeutics-showcases-immunotherapy-leadership-at-sitc-2025-demonstrating-integration-of-clinical-innovation-multi-omics-and-artificial-intelligence-to-advance-next-generation-immunotherapies-in-solid-tumors